Obsidian Therapeutics
Biotechnology, Health Care, Pharmaceutical
Founded in 1/1/15
Cambridge, Massachusetts, United States
For Profit
About Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.
Company Metrics
- Employees: 51-100
- Monthly Visits: 2398
- Tech Stack: 21 active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: 164500000 USD
- Last Funding: 115000000 USD (Series B)
- Funding Status: Early Stage Venture
Technology Stack
Obsidian Therapeutics actively uses 21 products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Pharmaceutical
Headquarters: Cambridge, Massachusetts, United States
Employees
- Jan Meulen - Chief Scientific Officer (LinkedIn)
- Jennifer Peterson - Chief People Officer (LinkedIn)
- Ryan Daws - Chief Financial Officer (LinkedIn)
- Shyam Subramanian - Chief Technical Officer (LinkedIn)